Connect with us

Health

Experimental drug helps patients lose nearly a quarter of body weight in early trials

Published

on

Experimental drug helps patients lose nearly a quarter of body weight in early trials

NEWYou can now listen to Fox News articles!

An experimental weight-loss medication was shown to help people lose nearly 25% of their body weight in early-stage 1a/2b trials.

The drug, amycretin — developed by Novo Nordisk — works by replicating two hunger hormones — amylin, which regulates appetite and creates a feeling of fullness, and glucagon-like peptide 1 (GLP-1), the same hormone that is used in Ozempic and Wegovy to suppress appetite and boost insulin secretion.

“Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule,” Martin Holst Lange, executive vice president and head of development at Novo Nordisk, previously said in a statement sent to Fox News Digital.

GRANDFATHER’S SIMPLE CHANGES REVERSED PRE-DIABETES DIAGNOSIS THAT LEFT HIM ‘PETRIFIED’

Advertisement

In the study, which included 125 overweight or obese adults, participants who received weekly injections of amycretin lost more weight than those who took a placebo, according to a press release from Novo Nordisk.

Those who got the highest doses (up to 60 mg) lost up to 24.3% pounds after 36 weeks, compared to just 1.1% for the placebo group, per the release.

An experimental weight-loss medication was shown to help people lose nearly 25% of their body weight in early-stage 1a/2b trials. (iStock)

A previous phase 1 trial of the oral (pill) version of amycretin also showed that treatment was “safe and tolerable,” with an “observed reduction in body weight” compared to placebo, the company stated.

Taking the pill once a day led to around 10% weight loss, and those who doubled the dose lost 13%.

Advertisement

YOUR DNA COULD BE STOPPING YOU FROM LOSING WEIGHT, NEW STUDY SUGGESTS

Another benefit the researchers highlighted is that people taking amycretin did not appear to hit a “weight-loss plateau,” continuing to shed pounds as long as they took it.

“The lack of weight loss plateauing indicates the possibility of achieving further weight reductions with extended treatment,” Agnes Gasoirek, a senior clinical pharmacology specialist at Novo Nordisk, wrote in the phase 1 study findings.

Novo Nordisk presented the latest findings at the American Diabetes Association in Chicago on June 22. ((Photo by LISELOTTE SABROE/Scanpix Denmark/AFP via Getty Images))

Novo Nordisk presented the latest findings at the American Diabetes Association in Chicago on June 22; they were also published in the medical journal Lancet.

Advertisement

“We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk, in the release. 

“Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule.”

“These results reflect our robust pipeline in obesity, [and] our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals.”

The most common side effects of amycretin, similar to other GLP-1s, were gastrointestinal symptoms — primarily nausea, vomiting and decreased appetite.

Advertisement

Adverse events were “mild to moderate” in severity, according to researchers. More frequent doses resulted in greater side effects.

It’s important to monitor these side effects closely, experts advise, as GI issues are common among patients with obesity. 

“Obesity is a chronic, multifactorial disease that requires a comprehensive, long-term approach,” a doctor said. (iStock)

“While the initial weight-loss outcomes are indeed encouraging, further studies are needed to ensure that the therapeutic benefits consistently outweigh the potential risks, especially with long-term administration,” Dr. Christine Ren-Fielding, director and chief of bariatric surgery at the NYU Langone Weight Management Program, previously told Fox News Digital.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Advertisement

While GLP-1-based drugs — including this new experimental pill — may show promising results, Ren-Fielding, who was not involved in the study, emphasized that they’re “not a cure-all for obesity.”

“Obesity is a chronic, multifactorial disease that requires a comprehensive, long-term approach,” she said at the time.

For more Health articles, visit www.foxnews.com/health

“Pharmacological treatments can play a significant role in managing the condition, but they are often most effective when combined with other interventions.”

Next, Novo Nordisk plans to prepare for phase 3 trials of the medication, in both oral and injectable forms, for the management of obesity.

Advertisement

Health

Goodbye, Late-Night Cravings! How To Curb Hunger and Make Weight Loss Easier

Published

on

Goodbye, Late-Night Cravings! How To Curb Hunger and Make Weight Loss Easier


Advertisement





How To Curb Late-Night Cravings and Make Weight Loss Easier | Woman’s World




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Lurking dementia risk exposed by breakthrough test 25 years before symptoms

Published

on

Lurking dementia risk exposed by breakthrough test 25 years before symptoms

NEWYou can now listen to Fox News articles!

A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge.

Advertisement

That’s according to new research from the University of California San Diego, which found that a specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk.

The researchers analyzed blood samples from 2,766 participants in the Women’s Health Initiative Memory Study in the late 1990s, according to the study’s press release. 

KEY FITNESS MEASURE IS STRONG PREDICTOR OF LONGEVITY AFTER CERTAIN AGE, STUDY FINDS

The women ranged from 65 to 79 years of age and showed no signs of cognitive decline at the start of the study.

After tracking the participants for up to 25 years, the researchers concluded that the biomarker phosphorylated tau 217 (p-tau217) was “strongly associated” with future mild cognitive impairment and dementia. 

Advertisement

A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge. (iStock)

Women who had higher levels of p-tau217 at the beginning of the study were “much more likely” to develop the disease. The findings were published today in JAMA Network Open.

“The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” first author Aladdin H. Shadyab, a UC San Diego associate professor of public health and medicine, told Fox News Digital. 

“These biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia.”

“Our findings show that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms begin,” he added.

Advertisement

This long lead time could open the door to earlier prevention strategies and more targeted monitoring, rather than waiting until memory problems are already affecting daily life, according to Shadyab.

A specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk. (iStock)

“As the research advances, these biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia,” he said.

This risk relationship wasn’t the same across the board, however. Women over 70 with higher p-tau217 levels had “poorer cognitive outcomes” compared to those under 70, as did those with the APOE ε4 gene, which is a known risk factor for Alzheimer’s disease.

Advertisement

The study also found that p-tau217 was a stronger predictor of dementia in women who were randomly assigned to receive estrogen and progestin hormone therapy compared to those who received a placebo.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” said senior author Linda K. McEvoy, senior investigator at Kaiser Permanente Washington Health Research Institute and professor emeritus at the Herbert Wertheim School of Public Health, in the release. 

“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” a researcher said. (iStock)

“This is important for accelerating research into the factors that affect the risk of dementia and for evaluating strategies that may reduce risk.”

Advertisement

Blood tests for Alzheimer’s disease are still being studied and are not recommended for routine screening in people without symptoms, Shadyab noted. 

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

More research is needed before this approach can be considered for clinical use prior to cognitive symptoms. 

Future studies should investigate how other factors — like genetics, hormone therapy and age-related medical conditions — might interact with plasma p-tau217, the researchers added.

CLICK HERE FOR MORE HEALTH STORIES

Advertisement

“The study examined only older women, so the findings may not necessarily apply to men or younger populations,” Shadyab noted. “We also examined overall dementia outcomes rather than specific subtypes such as Alzheimer’s disease.”

Continue Reading

Health

Key fitness measure is strong predictor of longevity after certain age, study finds

Published

on

Key fitness measure is strong predictor of longevity after certain age, study finds

NEWYou can now listen to Fox News articles!

For women over 60, muscle strength plays a critical role in longevity, a new study confirms.

Researchers at the University at Buffalo, New York, followed more than 5,000 women between the ages of 63 and 99, finding that those with greater muscle strength had a significantly lower risk of death over an eight-year period.

The findings were published in JAMA Network Open.

EXERCISE AFFECTS THE HEART IN A HIDDEN, POWERFUL WAY BY REWIRING NERVES, STUDY FINDS

Advertisement

Muscle function was measured using grip strength and how quickly participants could complete five unassisted sit-to-stand chair raises. 

These are two tests commonly used in clinical settings to evaluate muscle function in older adults, the researchers noted.

A recent study shows that stronger muscle strength in women over 60 is linked to a lower risk of death over eight years. (iStock)

“In a community cohort of ambulatory older women, muscular strength was associated with significantly lower mortality rates, even when we accounted for usual physical activity and sedentary time measured using a wearable monitor, gait speed and blood C-reactive protein levels,” study lead author Michael LaMonte, research professor of epidemiology and environmental health at the University at Buffalo, told Fox News Digital.

“Movement is the key — just move more and sit less.”

Advertisement

Many earlier studies did not include those objective measurements, making it difficult to determine whether muscle strength itself was linked to longevity, according to LaMonte. “Our study was able to better isolate the association between strength and death in later life,” he added.

Even for women who don’t get the recommended amount of aerobic physical activity, which is at least 150 minutes per week, muscle strength remained important for longevity, the researchers found.

Women with greater muscle strength were more likely to live longer, even if they did not meet the recommended amount of aerobic exercise. (iStock)

“The findings of lower mortality in those who had higher strength but were not meeting current national guidelines on aerobic activity were somewhat intriguing,” LaMonte said.

Advertisement

CLICK HERE FOR MORE LIFESTYLE STORIES

Federal guidelines recommend strengthening activities one to two days per week, targeting major muscle groups.

Resistance training does not have to require a gym membership, LaMonte noted. These exercises can be performed using free weights, resistance bands, bodyweight movements or even household items, such as soup cans.

Experts recommend working major muscle groups one or two days a week using weights, bands or bodyweight exercises. (iStock)

“Movement is the key — just move more and sit less,” he said. “When we can no longer get out of the chair and move around, we are in trouble.”

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

LaMonte acknowledged several limitations of the study. The researchers assessed muscle strength in older age but did not explore how earlier levels in adulthood might influence long-term health outcomes.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“We were not able to understand how strength and mortality relate in younger ages,” he said, noting that future research should explore whether building strength earlier could have an even greater impact on longevity.

Advertisement
Continue Reading

Trending